Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/198384
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Marco, Daniel N. | - |
dc.contributor.author | Salas. Maria Queralt | - |
dc.contributor.author | Gutiérrez García, Gonzalo | - |
dc.contributor.author | Monge Escartín, Inés | - |
dc.contributor.author | Riu, Gisela | - |
dc.contributor.author | Carcelero, Esther | - |
dc.contributor.author | Roma, Joan Ramon | - |
dc.contributor.author | Llobet, Noemí | - |
dc.contributor.author | Arcarons, Jordi | - |
dc.contributor.author | Suárez Lledó, María | - |
dc.contributor.author | Martínez, Nuria | - |
dc.contributor.author | Pedraza, Alexandra | - |
dc.contributor.author | Domenech, Ariadna | - |
dc.contributor.author | Rosiñol, Laura | - |
dc.contributor.author | Fernández Avilés, Francesc | - |
dc.contributor.author | Urbano Ispizua, Álvaro | - |
dc.contributor.author | Rovira, Montserrat | - |
dc.contributor.author | Brunet i Serra, Mercè | - |
dc.contributor.author | Martínez, Carmen | - |
dc.date.accessioned | 2023-05-23T16:17:50Z | - |
dc.date.available | 2023-05-23T16:17:50Z | - |
dc.date.issued | 2022-12-09 | - |
dc.identifier.issn | 1424-8247 | - |
dc.identifier.uri | http://hdl.handle.net/2445/198384 | - |
dc.description.abstract | Tacrolimus (Tac) is a pivotal immunosuppressant agent used to prevent graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (alloHSCT). Tac is characterized by a narrow therapeutic window and a high inter-patient and intra-patient pharmacokinetic variability (IPV). Although high IPV of Tac concentrations has been associated with adverse post-transplant outcomes following solid organ transplantation, the effects of Tac IPV on alloHSCT recipients have not been determined. Tac IPV was therefore retrospectively evaluated in 128 alloHSCT recipients receiving high-dose post-transplant cyclophosphamide (PTCy) and the effects of Tac IPV on the occurrence of acute GVHD (aGVHD) were analyzed. Tac IPV was calculated from pre-dose concentrations (C0) measured during the first month after Tac initiation. The cumulative rates of grades II-IV and grades III-IV aGVHD at day +100 were 22.7% and 7%, respectively. Higher Tac IPV was associated with a greater risk of developing GVHD, with patients having IPV > 50th percentile having significantly higher rates of grades II-IV (34.9% vs. 10.8%; hazard ratio [HR] 3.858, p < 0.001) and grades III-IV (12.7% vs. 1.5%; HR 9.69, p = 0.033) aGVHD than patients having IPV ? 50th percentile. Similarly, patients with IPV > 75th percentile had higher rates of grades II-IV (41.9% vs. 16.5%; HR 3.30, p < 0.001) and grades III-IV (16.1% vs. 4.1%; HR 4.99, p = 0.012) aGVHD than patients with IPV ? 75th percentile. Multivariate analyses showed that high Tac IPV (>50th percentile) was an independent risk factor for grades II-IV (HR 2.99, p = 0.018) and grades III-IV (HR 9.12, p = 0.047) aGVHD. Determination of Tac IPV soon after alloHSCT could be useful in identifying patients at greater risk of aGVHD. | - |
dc.format.extent | 14 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/ph15121529 | - |
dc.relation.ispartof | Pharmaceuticals, 2022, vol. 15, num. 12 | - |
dc.relation.uri | https://doi.org/10.3390/ph15121529 | - |
dc.rights | cc by (c) Marco, Daniel N. et al, 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) | - |
dc.subject.classification | Trasplantament d'òrgans | - |
dc.subject.classification | Cèl·lules mare | - |
dc.subject.other | Transplantation of organs | - |
dc.subject.other | Stem cells | - |
dc.title | Impact of Early Intrapatient Variability of Tacrolimus Concentrations on the Risk of Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-05-02T07:59:48Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.idimarina | 9334081 | - |
dc.identifier.pmid | 36558980 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Impact of Early Intrapatient Variability of Tacrolimus_Pharmaceuticals.pdf | 1.16 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License